EZH2 and acute myeloid leukemia: DNMT3AR882H upregulates the cyclin-dependent kinase CDK1, which competes with EZH2 for binding to the ADD domain, thereby inhibiting the EZH2 methyltransferase activity and inducing AML [142, 143].